Developments in laboratory techniques for prenatal diagnosis

Current Opinion in Obstetrics and Gynecology

Volumn 14, Issue 2, 2002, Pages 161-168

  Miny, Peter ^a   Tercanli, Sevgi ^a   Holzgreve, Wolfgang ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

AMNIOCENTESIS; ANEUPLOIDY; CELL NUCLEUS; CHORION VILLUS SAMPLING; CHROMOSOME ABERRATION; DNA POLYMORPHISM; EARLY DIAGNOSIS; FIRST TRIMESTER PREGNANCY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE; LABORATORY DIAGNOSIS; MATERNAL PLASMA; MATERNAL SERUM; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

AMNIOCENTESIS; ANEUPLOIDY; CHROMOSOME DISORDERS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; POLYMERASE CHAIN REACTION; PREGNANCY; PREIMPLANTATION DIAGNOSIS; PRENATAL DIAGNOSIS; RISK ASSESSMENT;

EID: 0036211581     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200204000-00010     Document Type: Review

References (112)

1. Classifying by colors: FISH-based genome analysis
2. Scanning for telomeric deletions and duplications and uniparental disomy using genetic markers in 120 children with malformations
3. STRBase: A short tandem repeat DNA database for the human identity testing community
4. The application of fluorescence in-situ hybridization to prenatal diagnosis
5. Rapid prenatal diagnosis of chromosome aneuploidies by interphase fluorescence in situ hybridization: A one-year clinical experience with high-risk and urgent fetal and postnatal samples
6. Role of amniotic fluid interphase fluorescence in situ hybridization (FISH) analysis in patient management
7. Prenatal diagnosis using interphase fluorescence in situ hybridization (FISH): 2-Year multi-center retrospective study and review of the literature
8. Fluorescence in situ hybridization (FISH) for rapid detection of aneuploidy: Experience in 911 prenatal cases
9. Rapid detection of chromosome aneuploidies by prenatal interphase FISH (fluorescence in situ hybridization) and its clinical utility in Japan
10. Technical and clinical assessment of fluorescence in situ hybridization: An ACMG/ASHG position statement. I. Technical considerations
11. Interphase FISH with chromosome-specific protelomere probes for rapid prenatal diagnosis in a reciprocal translocation carrier
12. Detection of maternal cell contamination in amniotic fluid cell cultures using fluorescent labelled microsatellites
13. Detection of aneuploidy in chromosomes X, Y, 13, 18 and 21 by QF-PCR in 662 selected pregnancies at risk
14. A large-scale evaluation of amnio-PCR for the rapid prenatal diagnosis of fetal trisomy
15. Development and implementation of a new rapid aneuploidy diagnostic service within the UK National Health Service and implications for the future of prenatal diagnosis
16. Advances in antenatal screening for Down Syndrome
17. Integrating antenatal Down's syndrome screening
18. First trimester biochemical screening for Down syndrome: Free beta hCG versus intact hCG
19. Response to Hallahan et al.
20. First trimester PAPP-A in the detection of non-Down syndrome aneuploidy
21. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results
22. Maternal serum screening for fetal trisomy 18: Benefits of patient-specific risk protocol
23. Maternal serum activin A and inhibin A in trisomy 18 pregnancies at 10-14 weeks
24. Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester
25. The influence of parity and gravidity on first trimester markers of chromosomal abnormality
26. First trimester markers of trisomy 21 and the influence of maternal cigarette smoking status
27. First-trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction
28. First trimester screening for Down syndrome and assisted reproduction: No basis for concern
29. Between pregnancy biological variability of first trimester markers of Down syndrome: Implications for screening in subsequent pregnancies
30. Pre-implantation genetic diagnosis
31. Preimplantation genetic diagnosis: Applications for molecular medicine
32. Preimplantation genetic diagnosis (PGD): The Gothenburg experience
33. Healthy births and ongoing pregnancies obtained by preimplantation genetic diagnosis in patients with advanced maternal age and recurrent implantation failure
34. The Brussels' experience of more than 5 years of clinical preimplantation genetic diagnosis
35. ESHRE preimplantation genetic diagnosis (PGD) consortium: Data collection II (May 2000)
36. ESHRE guidelines for good practice in IVF laboratories
37. Neonatal outcome of preimplantation genetic diagnosis by polar body removal: The first 109 infants
38. Tenth anniversary of preimplantation genetic diagnosis
39. Assessing the chromosome copy number in metaphase II oocytes by sequential fluorescence in situ hybridization
40. Lack of cell cycle checkpoints in human cleavage stage embryos revealed by a clonal pattern of chromosomal mosaicism analysed by sequential multicolour FISH
41. An improved fixation technique for fluorescence in situ hybridization for preimplantation genetic diagnosis
42. Gamete segregation in female carriers of Robertsonian translocations
43. Perfect endings: A review of subtelomeric probes and their use in clinical diagnosis
44. Outcome of preimplantation genetic diagnosis of translocations
45. Case-specific, breakpoint-spanning DNA probes for analysis of single interphase cells
46. Highly abnormal cleavage divisions in preimplantation embryos from translocation carriers
47. Detection of chromosome translocation products in single interphase cell nuclei
48. Preimplantation genetic diagnosis of pericentric inversions
49. Comprehensive chromosomal analysis of human preimplantation embryos using whole genome amplification and single cell comparative genomic hybridization
50. Use of PRINS for preconception screening of polar bodies for common aneuploidies
51. Detection of structural and numerical chromosome abnormalities in interphase cells using spectral imaging
52. Towards a full karyotype screening of interphase cells: 'FISH and chip' technology
53. Chromosomal abnormalities in the first and second polar body
54. First specific preimplantation genetic diagnosis for ornithine transcarbamylase deficiency
55. Preimplantation genetic diagnosis of the fragile X syndrome by use of linked polymorphic markers
56. Six unaffected livebirths following preimplantation diagnosis for spinal muscular atrophy
57. Allele-specific amplification for preimplantation genetic diagnosis (POD) of spinal muscular atrophy
58. A successful strategy for preimplantation genetic diagnosis of myotonic dystrophy using multiplex fluorescent PCR
59. Preimplantation genetic diagnosis for sickle-cell anemia and for beta-thalassemia
60. Preembryonic diagnosis for sickle cell disease
61. Single intragenic microsatellite preimplantation genetic diagnosis for cystic fibrosis provides positive allele identification of all CFTR genotypes for informative couples
62. Preimplantation genetic diagnosis of compound heterozygous mutations leading to ablation of plakophilin-1 (PKP1) and resulting in skin fragility ectodermal dysplasia syndrome: A case report
63. Scientists screen embryo for genetic predisposition to cancer
64. Preimplantation testing for phenylketonuria
65. A pregnancy following PGD for X-linked dominant [correction of X-linked autosomal dominant] incontinentia pigmenti (Bloch-Sulzberger syndrome): Case report
66. Preimplantation diagnosis for Fanconi anemia combined with HLA matching
67. Ethical implications of a new application of preimplantation diagnosis
68. Reliability of preimplantation diagnosis for single gene disorders
69. A comparison of different lysis buffers to assess allele dropout from single cells for preimplantation genetic diagnosis
70. Controlling misdiagnosis errors in preimplantation genetic diagnosis: A comprehensive model encompassing extrinsic and intrinsic sources of error
71. Fetal cells in the mother: From genetic diagnosis to diseases associated with fetal cell microchimerism
72. Prenatal diagnosis using fetal cells and free fetal DNA in maternal blood
73. Fetal cells in maternal blood
74. Significant fetal-maternal hemorrhage after termination of pregnancy: Implications for development of fetal cell microchimerism
75. Fetal cell microchimerism in tissue from multiple sites in women with systemic sclerosis
76. Microchimerism in a female patient with systemic lupus erythematosus
77. Increased fetal erythroblasts in women who subsequently develop preeclampsia
78. Elevation in erythroblast count in maternal blood before the onset of preeclampsia
79. Fetal DNA in maternal plasma: Biology and diagnostic applications
80. Quantification of circulating DNA: In the preparation lies the rub
81. Fetal DNA in maternal plasma: Emerging clinical applications
82. Large amounts of cell-free fetal DNA are present in amniotic fluid
83. Apoptosis in fetal nucleated erythrocytes circulating in maternal blood
84. More than one-half of the erythroblasts in the fetal circulation and cord blood are TUNEL positive
85. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma
86. Fetal DNA in maternal plasma is elevated in pregnancies with aneuploid fetuses
87. High levels of fetal erythroblasts and fetal extracellular DNA in the peripheral blood of a pregnant woman with idiopathic polyhydramnios: Case report
88. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia
89. Prenatal DNA diagnosis of a single-gene disorder from maternal plasma
90. Prenatal identification of fetal genetic traits
91. Prenatal detection of fetal Down's syndrome from maternal plasma
92. Prenatal detection of fetal Down's syndrome
93. Non-invasive prenatal diagnosis of Down's syndrome
94. Detection of fetal trisomy 18 by short-term culture of maternal peripheral blood
95. Clonal culture of fetal cells from maternal blood
96. Clonal culture of fetal cells from maternal blood
97. How useful is the in vitro expansion of fetal CD34+ progenitor cells from maternal blood samples for diagnostic purposes?
98. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow
99. Diagnosis of trisomy 21 in fetal nucleated erythrocytes from maternal blood by use of short tandem repeat sequences
100. Simultaneous fetal cell identification and diagnosis by epsilon-globin chain immunophenotyping and chromosomal fluorescence in situ hybridization
101. Non-invasive exclusion of fetal aneuploidy in an at-risk couple with a balanced translocation
102. Prenatal diagnosis on fetal cells from maternal blood: Practical comparative evaluation of the first and second trimesters
103. Optimization of nucleated red blood cell (NRBC) recovery from maternal blood collected using both layers of a double density gradient
104. An examination of different Percoll density gradients and magnetic activated cell sorting (MACS) for the enrichment of fetal erythroblasts from maternal blood
105. HLA-G expression in trophoblast cells circulating in maternal peripheral blood during early pregnancy
106. Microsatellite analysis provides efficient confirmation of fetal trophoblast isolation from maternal circulation
107. Transcervical sampling as a means of detection of fetal cells during the first trimester of pregnancy
108. Non-invasive early prenatal diagnosis using fluorescent in situ hybridization on transcervical cells: Comparison of two different methods for retrieval
109. The sequence of the human genome
110. Initial sequencing and analysis of the human genome